leisure time -WSS

leisure time

author：comprehensive 2025-09-10 04:17:15 - browse：5

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Liquid biopsy for lung cancer is launched by Delfi

hotspot

WSS

CDC's new outbreak response network to include Northeastern

Intarcia’s device

Experts study whether long Covid risk adds up with each reinfection

Bristol 'take

Analysis of telehealth claims data suggest service duplication

Intarcia’s device

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Was Amgen transparent enough on FDA's concern on cancer drug?

Alkermes shareholders re

Liquid biopsy for lung cancer is launched by Delfi

United colonoscopy coverage change 'may cost lives,' doctors say

FDA rejects Alnylam's heart disease treatment over insufficient data

The high cost of giving birth even with insurance

Microbiome research is starting to find links to chronic diseases

United colonoscopy coverage change 'may cost lives,' doctors say

Second xenotransplant done with gene

explore

It's been 20 years since Dolly the sheep. Where's my clone?

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Phenylephrine and the overlooked value of the placebo effect

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Senators: Long

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

focus

hotspot

focus

focus